Curious the Navitus as a PBM is publishing this considering that it maintains exclusionary formularies which exclude generic versions of the GLP-1 Victoza or Saxenda (liraglutide) from Teva and Biocon (with more now pending regulatory approval decisions) from its formularies, raising questions as to how much influence PBM formulary managers have in driving formulary decisions when confronted by an employer plan sponsor demanding rebate pass-thru
Similar to the bFGF-treated group, on the 18th day postwounding, the BPC-157-treated group showed nearly 80% wound closure, whereas rats left untreated recovered by 60% at most
It acts on the brains appetite centers, leading to reduced food intake and increased satiety
In the US, this shift is already operational: 42% of restaurant operators have added or are actively considering GLP-1-friendly options to capture diners prioritizing lean proteins and fresh produce
Previous studies have shown that branched-chain amino acids are associated with insulin resistance and the risk of T2D (8689)
Gastrointestinal discomfort has been reported by some Ipamorelin users
